

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all previously submitted listing of claims:

1. **(Currently amended)** A method for inhibiting growth of cancer cells comprising administering a composition comprising ~~an~~ a non-radiolabeled antibody or a fragment thereof that specifically binds to a first epitope on a ~~circulating~~ tumor-associated antigen produced by cancer cells, thereby generating an immune response to a second epitope on the antigen and eliciting a host immune response against cancer cells producing the antigen, ~~wherein said antibody is non-radiolabeled and wherein said tumor-associated antigen is selected from the group consisting of CA19.9, CA15.3, and CA125.~~
2. **(Currently amended)** The method of claim 1 wherein the antibody is selected from the group consisting of a monoclonal antibody, a chimeric antibody, a humanized antibody, a genetically engineered ~~monoclonal~~ antibody, a Fab fragment, a F(ab')₂ fragment, a single chain antibody and a single chain antibody fragment.
- 3.-6. **(Cancelled)**
7. **(Previously presented)** The method of claim 1 wherein the host immune response is a cellular immune response against said cancer cells.
8. **(Previously presented)** The method of claim 1 wherein the host immune response is a humoral immune response against said cancer cells.
9. **(Previously presented)** The method of claim 1 wherein the host immune response is both a humoral immune response and a cellular response against said cancer cells.
10. **(Currently amended)** A method for eliciting a therapeutic immune response in a host comprising administering to the host a composition comprising ~~an~~ a non-radiolabeled antibody or a fragment thereof that specifically binds to a first epitope on a ~~circulating~~ tumor-associated antigen, thereby generating a therapeutic host immune response against a second epitope on the antigen, ~~wherein said antibody is non-radiolabeled and wherein said tumor-associated antigen is selected from the group consisting of CA19.9, CA15.3, and CA125.~~

11-15. (Cancelled)

16. (Currently amended) A therapeutic composition comprising ~~an~~ a non-radiolabeled antibody or a fragment thereof specific for a first epitope on a ~~circulating~~ multi-epitopic *in vivo* tumor-associated antigen, which antigen does not elicit an effective host immune response, wherein when the antibody present in the composition specifically binds a first epitope on the antigen and forms an antibody/antigen pair, an effective host immune response is elicited against a second epitope on the antigen, ~~and wherein said antibody is non-radiolabeled and~~ wherein said tumor-associated antigen is selected from the group consisting of CA19.9, CA15.3, and CA125.

17. (Currently Amended) The therapeutic composition of claim 16, wherein the antibody is selected from the group consisting of a monoclonal antibody, a chimeric antibody, a humanized antibody, a genetically engineered ~~monoclonal~~ antibody, a Fab fragment, a F(ab')₂ fragment, a single chain antibody and a single chain antibody fragment.

18. (Currently amended) The therapeutic composition of claim 16, further comprising one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, ~~one or more imaging reagents~~, one or more pharmaceutically acceptable carriers, and/or physiologically acceptable saline.

19. (Currently amended) The method of any one of claims 1-2, 4 and 7-10, wherein the composition further comprises one or more adjuvants, one or more carriers, ~~one or more excipients~~, one or more stabilizers, one or more imaging reagents, one or more pharmaceutically acceptable carriers, and/or physiologically acceptable saline.

20. (Previously presented) The method of any one of claims 1-2, 4 and 7-10, wherein the composition is administered by any acceptable route selected from the group consisting of intravenous injection, subcutaneous injection, intradermal injection, intramuscular injection, and intralymphatic injection.

21. **(Currently amended)** The method of any one of claims 1-2, 4 and 7-10, wherein the ~~circulating~~ tumor-associated antigen is a soluble antigen.
22. **(Currently amended)** The method of any one of claims 1-2, 4 and 7-10, wherein binding of the antibody in the composition to the first epitope on the ~~circulating~~ tumor-associated antigen ~~presents~~ results in the presentation of one or more epitopes on the antigen other than the first epitope.
23. **(Cancelled)**
24. **(Previously presented)** The method of any one of claims 1-2, 4 and 7-9, wherein the cancer is selected from the group consisting of gastrointestinal, breast, ovarian, lung, colorectal, renal cell, prostate, endometrial, bone, and pancreatic.
25. **(Previously presented)** The method of any one of claims 1-2, 4 and 7-10, wherein the therapeutic composition is administered at a dose of about 2 mg/patient.
26. **(Previously presented)** The method of any one of claims 1-2, 4 and 7-10, wherein the therapeutic composition is administered at a dose of from about 0.1 μg to about 200 μg antibody per kg of body weight of a patient.
27. **(Previously presented)** The therapeutic composition of claim 16, wherein the composition is formulated for administration at a dose of about 2 mg/patient.
28. **(Previously presented)** The therapeutic composition of claim 16, wherein the composition is formulated for administration at a dose of from about 0.1 μg to about 200 μg antibody per kg of body weight of a patient.
29. **(Cancelled)**